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Research
The 26 April 1986 accident at the Chornobyl 
(Chernobyl) nuclear power plant contaminated 
large areas of northern Ukraine as well as parts 
of Belarus and the Russian Federation. The 
environmental fallout included radionuclides of 
iodine, primarily iodine-131 (131I), which con-
centrates in the thyroid gland (United Nations 
Scientific Committee on the Effects of Atomic 
Radiation 2000). The scientific evidence accu-
mulated since the accident points clearly to a 
substantial increase in thyroid cancer among 
those exposed as children (Cardis et al. 2005; 
Ivanov et al. 2006; Jacob et al. 1999; Likhtarov 
et al. 2006; Tronko et al. 2006b). However, 
research into possible effects of exposure on 
thyroid function has been limited, and the 
results have been inconsistent, largely because 
of issues in study design and lack of individual 
dose estimates (Eheman et al. 2003; Goldsmith 
et al. 1999; Kasatkina et al. 1997; Pacini et al. 
1998; Quastel et al. 1997; Saiko et al. 1997; 
Vermiglio et al. 1999; Vykhovanets et al. 
1997). A significant upward shift in thyroid- 
stimulating hormone (TSH) levels and 
increased rates of juvenile hypo  thyroidism 
in children exposed in Belarus and Ukraine 
because of the Chornobyl accident have been 
reported in some ecologic studies (Goldsmith 
et al. 1999; Quastel et al. 1997; Vykhovanets 
et al. 1997), but not in others (Kasatkina et al. 
1997; Pacini et al. 1998; Saiko et al. 1997; 
Vermiglio et al. 1999). Several studies, includ-
ing ours (Tronko et al. 2006a), suggested 
effects on thyroid auto  immunity (Pacini et al. 
1998; Vermiglio et al. 1999; Vykhovanets 
et al. 1997). We have assessed the prevalence 
of autoimmune thyroiditis (AIT) and elevated 
antibodies to thyroid peroxidase (ATPO) in 
a cohort of 12,240 individuals from Ukraine 
who were < 18 years of age at the time of the 
Chornobyl accident, with individual thyroid 
radioactivity measurements taken shortly after 
the accident (Tronko et al. 2006a). We found 
a significant dose–response relationship for the 
prevalence of elevated ATPO alone, but not 
for AIT.
Here, we extend analyses in this cohort 
to test the hypothesis that the prevalence of 
hypothyroidism is associated with individual 
131I thyroid dose estimates and/or that this 
relationship varies according to ATPO levels. 
Clarifying the relationship of hypothyroidism 
with radioiodines is important because of the 
widespread use of 131I in medical practice 
and concerns about health risks associated 
with the potential release of radioiodines from 
nuclear reactors.
Materials and Methods
Study population. A detailed description of 
the study design and methods was published 
previously (Stezhko et al. 2004). In brief, 
the cohort consists of individuals with direct 
meas  ure  ments of thyroid radioactivity made 
in May or June 1986 who were < 18 years 
of age on the day of the accident (26 April 
1986) and who resided in adjacent Chernihiv, 
Zhytomyr, or Kyiv oblasts (an oblast is an 
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Ba c k g r o u n d: Hypothyroidism is the most common thyroid abnormality in patients treated with 
high doses of iodine-131 (131I). Data on risk of hypothyroidism from low to moderate 131I thyroid 
doses are limited and inconsistent.
oB j e c t i v e: This study was conducted to quantify the risk of hypothyroidism prevalence in relation 
to 131I doses received because of the Chornobyl accident. 
Me t h o d s : This is a cross-sectional (1998–2000) screening study of thyroid diseases in a cohort of 
11,853 individuals < 18 years of age at the time of the accident, with individual thyroid radioactivity 
measurements taken within 2 months of the accident. We measured thyroid-stimulating hormone 
(TSH), free thyroxine, and antibodies to thyroid peroxidase (ATPO) in serum.
re s u l t s: Mean age at examination of the analysis cohort was 21.6 years (range, 12.2–32.5 years), with 
49% females. Mean 131I thyroid dose was 0.79 Gy (range, 0–40.7 Gy). There were 719 cases with 
hypothyroidism (TSH > 4 mIU/L), including 14 with overt hypothyroidism. We found a significant, 
small association between 131I thyroid doses and prevalent hypothyroidism, with the excess odds ratio 
(EOR) per gray of 0.10 (95% confidence interval, 0.03–0.21). EOR per gray was higher in individuals 
with ATPO ≤ 60 U/mL compared with individuals with ATPO > 60 U/mL (p < 0.001).
co n c l u s i o n s: This is the first study to find a significant relationship between prevalence of hypo-
thyroidism and individual 131I thyroid doses due to environmental exposure. The radiation increase 
in hypothyroidism was small (10% per Gy) and limited largely to subclinical hypothyroidism. 
Prospective data are needed to evaluate the dynamics of radiation-related hypothyroidism and 
clarify the role of antithyroid antibodies.
key w o r d s : Chernobyl nuclear accident, Chornobyl, dose–response relationship, hypothyroidism, 
ionizing radiation. Environ Health Perspect 117:745–750 (2009).  doi:10.1289/ehp.0800184 avail-
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administrative area similar in size to a state 
or province) or in the city of Kyiv, Ukraine, 
at the beginning of the study (Stezhko et al. 
2004). We based the present analysis on the 
data collected during the first screening exam-
ination conducted between 1998 and 2000. 
Figure 1 summarizes individuals we origi-
nally selected, traced, and screened (Stezhko 
et al. 2004), or excluded from the analysis. To 
assure that TSH measurements at first exami-
nation reflect spontaneous levels, we excluded 
from the analysis individuals who reported 
thyroid disease (n = 815, 90% with simple 
diffuse goiter) or thyroid surgery (n = 46) or 
intake of thyroid hormones (n = 27) before 
the first screening examination. We also 
excluded individuals without TSH or ATPO 
measurements (n = 146), mainly due to refusal 
to provide a serum sample, and those with 
measure  ments performed using the Amerlite 
assay at the beginning of the study before the 
Brahms assay became available (n = 272). 
The study was reviewed and approved by 
the institutional review boards of the par-
ticipating organizations in Ukraine and the 
United States, and all subjects gave written 
informed consent.
Screening examination. Individuals were 
screened either by a mobile medical team visit-
ing the local area or at the Research Institute 
of Endocrinology and Metabolism in Kyiv. 
Screening procedures included thyroid pal-
pation and ultrasonographic examination by 
an ultrasonographer and independent clinical 
examination and palpation by an endocrinolo-
gist; a serum sample and a spot urine sample 
were collected. A series of structured question-
naires eliciting information on demographics, 
individual and family medical history, and 
items relevant to thyroid dose estimation, such 
as residential history, milk and leafy vege-
table consumption, and iodine prophylaxis in 
May–June 1986, were administered by study 
  personnel (Stezhko et al. 2004).
Ultrasound examination. The thyroid was 
examined using a 7.5-MHz linear transducer 
(Toshiba 240; Toshiba Corp., Tokyo, Japan) 
with the subject supine and neck extended. 
The thyroid volume was calculated based on 
the volume of an ellipsoid (length × width × 
depth × 0.479) as described elsewhere (Brunn 
et al. 1981).
Serum assays. We measured TSH, ATPO, 
and free thyroxine (FT4) in serum samples with 
LUMitest immunochemiluminescence assays 
(Brahms Diagnostica GMBH, Heningsdorf, 
Germany) using a Berthold 953 luminometer 
(Berthold Technologies, GmbH & Co. KG, 
Bad Wildbad, Germany). We performed TSH 
and ATPO measurements for everyone with a 
sufficient serum sample (99% of the cohort), 
and performed FT4 measurements only for 
those whose TSH result was outside the refer-
ence range. We conducted all assays according 
to the manufacturer’s instructions.
Intraassay coefficients of variation (CVs) 
for the TSH assay at 0.03 and 2.0 mIU/L 
were 3.0% and 2.2%, respectively, and the 
inter  assay CVs were 10.9% and 2.8%, respec-
tively. Intraassay CVs for the ATPO assay 
at 84 and 375 U/mL were 8.1% and 6.5%, 
respectively, and the interassay CVs were 
11.4% and 7.7%, respectively. Intraassay CVs 
for the FT4 assay at 7.4 and 33.5 pmol/L were 
5.6% and 2.8%, respectively, and the inter-
assay CVs at 6.7 and 53.9 pmol/L were 9.0% 
and 7.3%, respectively.
Based on evaluation of the range of values 
in a sample from our cohort, we set reference 
limits for TSH between 0.3 and 4.0 mIU/L. 
We considered ATPO > 60 U/mL to be ele-
vated or positive, consistent with Brahms.
We set reference limits for FT4 between 
10.0 and 25.0 pmol/L based on Brahms’s 
  recommendation.
Iodine determination. We measured urinary 
iodine content, expressed in micrograms per 
liter, in spot urine samples using the Sandell–
Kolthoff reaction (Tronko et al. 2005). The 
analytic sensitivity of the assay was 6 µg/L.
Outcome definition. We defined hypo-
thyroidism as serum TSH concentration 
> 4.0 mIU/L, the upper limit of the reference 
range. We limited overt hypothyroidism to 
cases of hypothyroidism with serum FT4 con-
centration < 10 pmol/L, the lower limit of the 
reference range.
Dosimetry. Details of dosimetric methods 
have been published elsewhere (Likhtarev et al. 
2003, 2006; Likhtarov et al. 2005, 2006). 
The unique feature of our study is that doses 
were primarily based on thyroid radioactivity 
measurements taken within 8 weeks of the 
accident. Using these measurements, data on 
dietary and lifestyle habits, and environmen-
tal transfer models, we estimated individual 
131I thyroid doses and their uncertainties. 
The distributions of 1,000 individual thyroid 
dose estimates, obtained using a Monte Carlo 
procedure, were approximately lognormal 
(Likhtarev et al. 2003). For the present analy-
ses, we used the arithmetic means of the 1,000 
individual 131I dose realizations after adjust-
ment for the typical thyroid masses of the 
Ukrainian population, which were measured 
by the Sasakawa Memorial Health Foundation 
for children 5–16 years of age and by the 
Ukrainian Radiation Protection Institute for 
children < 5 years of age (Likhtarov I, personal 
communication). The arithmetic mean and 
the median of the individual 131I arithmetic 
means in the cohort were 0.79 and 0.26 Gy, 
respectively. The dose estimates are for 131I, 
which typically accounts for more than 90% 
of the total thyroid dose (Stezhko et al. 2004). 
We did not take into account the remaining 
portions of thyroid dose from external expo-
sure and from internal exposure to cesium and 
other isotopes of iodine. 
Statistical analysis. To estimate odds ratios 
(ORs) and compute the corresponding 95% 
confidence intervals (CIs), we conducted  Figure 1. Study flow diagram.
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Out of age range (n = 40)
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logistic regression analyses using the GMBO 
module of Epicure, version 1.8, for Microsoft 
Windows (Preston et al. 1993). We assumed 
that the hypothyroidism prevalence, γ(x, d), 
depends on a vector of covariates x that 
describes the background prevalence (i.e., in 
the absence of 131I exposure), and the esti-
mated 131I thyroid dose d. Components of x 
or adjustment factors included indicator vari-
ables for categories of sex, age at examination, 
oblast of residency at the time of screening, 
current smoking status, vitamin consumption, 
history of thyroid disease in relatives, calendar 
year and season of examination, serum ATPO, 
and urinary iodine level. Under a relative OR 
model, γ can be written as a product of the 
background hypothyroidism odds, denoted 
γ0(x), and a dose–response function, h(d). If 
the dose–response function, h, is linear in dose 
alone, the model is γ(x, d) = γ0(x) × (1 + βd), 
where β is the excess odds ratio (EOR), the 
parameter that measures the unit increase 
in EOR per unit increase in dose in grays   
(EOR/Gy). We evaluated deviations from the 
linear model by fitting the linear-quadratic 
and linear-exponential dose–response models, 
γ(x, d) = γ0(x) × (1 + βd + θd2) and γ(x, d) = 
γ0(x) × (1 + βd)*e–θd, respectively, where θ, is 
a parameter that measures nonlinearity. We 
evaluated the statistical significance of model 
parameters, test of trend, and comparison in 
goodness of fit between the models using like-
lihood ratio chi-square test with degrees of 
freedom (df) equal to the difference in number 
of parameters in compared models. All statisti-
cal tests were two-sided, and we considered 
p < 0.05 significant.
To evaluate interaction, we allowed the 
dose–response trend, β, to vary within J cate-
gories of different factors such as sex, age at 
exposure, and ATPO, and compared devi-
ance of the simple EOR model with a model 
that had J dose–response parameters. Under 
the null hypothesis of no interaction, the dif-
ference in model deviances asymptotically 
had a chi-square distribution with J – 1 df. A 
significant p-value indicated that the effect of 
radiation on hypothyroidism prevalence is not 
homogeneous across levels of the factor under 
investigation.
To investigate a potential bias from 
excluding the large number of subjects 
with prior self-reported thyroid diseases, we 
repeated analyses including these individuals.
Results
Among 11,853 individuals included in the 
analysis, 719 (6.1%) had TSH levels > 4 mIU/L 
and 22 (0.2%) had TSH levels > 10 mIU/L. 
Among individuals with elevated TSH levels,   
14 (1.9%) had overt hypo  thyroidism. 
Excluding cases with overt hypo  thyroidism had 
no effect on the study results, so we retained 
these cases in the analysis.
The analysis cohort was 49% female. At 
the time of the accident, the mean ± SD age 
of cohort members was 8 ± 4.7 years, with 
a mean age at examination (1998–2000) of 
21.6 ± 4.9 years. The mean (median) 131I thy-
roid dose was 0.79 (0.26) Gy.
Background prevalence of hypothyroid-
ism. Table 1 summarizes selected associations 
for background prevalence of hypothyroidism. 
The prevalence of hypothyroidism was some-
what lower in females than males (p = 0.07). 
Residents of Kyiv and Chernihiv oblasts had 
20% lower risk compared with residents of 
Zhytomyr Oblast (p = 0.02). We found no dif-
ference in prevalence between rural and urban 
residents (p = 0.48, not shown). Current smok-
ers had lower risk of hypothyroidism preva-
lence compared with nonsmokers (p < 0.001). 
Individuals who reported intake of multi-
vitamins had lower risk of hypothyroidism than 
did those who did not (p = 0.04). Presence 
of any thyroid disease in at least one relative 
somewhat increased risk of hypothyroidism 
(p = 0.12). Individuals examined in 1998 or 
2000 had lower risk of hypothyroidism than 
those examined in 1999 (p < 0.001). There was 
a suggestion that risk of hypothyroidism was 
lower among individuals examined in spring 
or summer compared with those examined in 
the winter (p = 0.08). Individuals with ATPO 
> 60 U/mL had almost twice the risk of hypo-
thyroidism compared with those with ATPO 
≤ 60 U/mL (p = 0.001). We found no evi-
dence that the risk of hypothyroidism varied 
with iodine intake, using several indicators: 
levels of urinary iodine (p = 0.89), presence of 
Table 1. ORs and 95% CIs for background prevalence of hypothyroidism (TSH > 4 mIU/L) among individuals 
exposed to 131I from the Chornobyl accident.
  Cases  Noncases  Rate 
Parameter   (n = 719)   (n = 11,134)  per 1,000  OR (95% CI)a
Sex
  Male  363   5,723  59.64  1.00 (Referent)
  Female  356  5,411  61.73  0.86 (0.58–1.28)
  p-Value homogeneity: 0.07, df = 1
Place of residency
  Zhytomyr Oblast  197  3,044  60.78  1.00 (Referent)
  Kyiv Oblast/Kyiv City  123  2,269  51.42  0.80 (0.62–1.03)
  Chernihiv Oblast  399  5,821  61.15  0.78 (0.58–0.87)
  p-Value homogeneity: 0.02, df = 2
Current smoking 
  No  536  7,343  68.03  1.00 (Referent)
  Yes  183  3,791  46.05  0.71 (0.58–0.87)
  p-Value homogeneity: < 0.001, df = 1
Vitamin consumption
  No  690  10,477  61.79  1.00 (Referent)
  Yes  29  657  42.27  0.68 (0.45–0.98)
  p-Value homogeneity: 0.04, df = 1
Thyroid disease history in relatives
  No   486  7,522  60.69  1.00 (Referent)
  At least one relative affected  71  811  80.50  1.24 (0.94–1.61)
  p-Value homogeneity: 0.12, df = 1
  Unknown  162   2,801  54.67  0.88 (0.73–1.06)
Year of examination
  1998  23  1,284  17.60  0.12 (0.07–0.19 )
  1999  244  2,577  86.49  1.00 (Referent)
  2000  452  7,273  58.51  0.80 (0.67–0.96)
  p-Value homogeneity: < 0.001, df = 2
Season of examination
  December–February  154  1,950  73.19  1.00 (Referent)
  March–May   232  3,195  67.70  0.81 (0.64–1.02)
  June–August  150  2,722  52.23  0.74 (0.58–0.94)
  September–November   183  3,267  53.04  0.90 (0.71–1.15)
  p-Value homogeneity: 0.08, df = 3
ATPO level (U/mL)
  ≤ 60  591  10,468  56.46  1.00 (Referent)
  > 60  128  1,385  95.31  1.81 (1.47–2.23)
  p-Value homogeneity : < 0.001, df = 1 
Urinary iodine (µg/L)
  < 20  101  1,428  66.06  1.08 (0.83–1.40)
  20–49  284  4,321  61.67  1.03 (0.85–1.25)
  50–99  191  3,093  58.16  1.00 (Referent)
  ≥ 100  73  1,262  54.68  0.95 (0.72–1.26)
  p-Value homogeneity: 0.89, df = 3
  Missing/unknown   70   1,030  63.64  1.10 (0.83–1.48)
aAll analyses performed with adjustment for sex, age at examination by sex, place of residency, current smoking status, 
vitamin consumption, family history of thyroid disease, year and season of examination, ATPO level, and 131I thyroid dose 
based on linear EOR model.Ostroumova et al.
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diffuse goiter (p = 0.56; data not shown), or 
large thyroid volume (≥ 15 mL) at ultrasound 
(p = 0.20; data not shown).
Table 2 shows associations for background 
prevalence of hypothyroidism with age at 
examination, by sex. Although the risk of 
hypothyroidism decreased with age for both 
sexes, the decrease was more pronounced and 
gradual in males than in females (p < 0.001).
Radiation effects. Table 3 shows adjusted 
thyroid dose category-specific ORs for hypo-
thyroidism. We chose these categories to 
assure reasonably even proportional incre-
ment in 131I dose. The ORs increased with 
dose over the entire range (p = 0.004). Based 
on the simple linear EOR model, we found a 
highly significant dose–response (p = 0.003) 
with an estimated EOR/Gy of 0.10 (95% CI, 
0.03– to 0.21). Figure 2 presents the category-
specific ORs and fitted linear dose response. 
We found little evidence of nonlinearity in the 
dose response when we compared the linear fit 
with a linear-quadratic model (p = 0.89) or a 
linear-exponential model (p = 0.87). The linear 
dose–response trend was significant at doses 
< 5 Gy, with an estimated EOR/Gy of 0.16 
(95% CI, 0.02 to 0.34), and there were posi-
tive, although not significant, linear trends at 
dose ranges < 3 Gy and < 2 Gy with estimated 
EORs/Gy of 0.13 (95% CI, –0.04 to 0.36) 
and 0.15 (95% CI, –0.07 to 0.45), respectively. 
If we defined subclinical hypothyroidism as 
TSH > 3.0 mIU/L, the magnitude of the dose 
response was similar, with an estimated EOR/
Gy of 0.08 (95% CI, 0.03 to 0.15) over the 
entire dose range. Similarly, when we repeated 
the dose–response analyses including individu-
als with a history of thyroid disease or intake of 
thyroid hormones before the first screening, the 
EOR/Gy was 0.09 (95% CI, 0.03 to 0.17).
Table 4 summarizes variation in the dose–
response slope according to selected charac  teris-
tics. EOR per gray did not vary significantly 
by sex (p = 0.36), age at exposure (p = 0.56), 
current smoking status (p = 0.46), family his-
tory of thyroid disease (p = 0.79; data not 
shown), oblast of residency (p = 0.16; data 
not shown), year of examination (p = 0.83; 
data not shown), or levels of urinary iodine 
(p = 0.92). We observed highly significant varia-
tion of the dose–response according to ATPO 
levels (p < 0.001). Individuals with ATPO   
≤ 60 U/mL had a higher EOR per gray com-
pared with individuals with ATPO > 60 U/mL, 
for whom the EOR per gray did not signifi-
cantly differ from zero, as evidenced by CIs.
Discussion
We found a significant linear dose–response 
relationship between low to moderate 131I 
doses to the thyroid and prevalence of sub-
clinical hypothyroidism among individuals 
who were children or adolescents at the time 
of the Chornobyl accident and underwent an 
in-depth thyroid examination 12–14 years 
later. After controlling for a variety of poten-
tial confounders, the overall estimated EOR 
per gray was 0.10 (95% CI, 0.03 to 0.21). 
EOR per gray was higher in individuals with 
ATPO levels ≤ 60 U/mL compared with those 
with ATPO > 60 U/mL.
We do not believe that the results of our 
study could be attributed to selection bias, 
even though we screened 40.9% of those 
selected from the file of thyroid activity mea-
surements, representing 67.5% of those invited 
to participate, because distribution of meas-
ured thyroid radioactivity was similar among 
participants (n = 13,243) and nonparticipants 
(n = 19,142) (Stezhko et al. 2004). Further, 
we adjusted our analyses for a variety of pos-
sible confounders and effect modifiers to avoid 
any potential effects of differential distribution 
of such variables among participants and non-
participants. Additional exclusion of individu-
als with self-reported history of thyroid disease 
or intake of thyroid hormones before the first 
screening is unlikely to have introduced bias 
because the results of analyses including and 
excluding these individuals were similar.
We did not take into account the impact 
of uncertainties in dose estimates in our 
analysis aimed at providing initial evidence 
on the relationship between prevalent hypo-
thyroidism and environmental 131I exposure. 
We previously reported that uncertainties in 
estimates of the individual 131I thyroid doses 
were approximately lognormally distributed, 
with geometric standard deviations ranging 
from 1.6 to 5.0 and a median of 1.7 (Likhtarev 
et al. 2003). These uncertainties are compara-
ble with, and in most cases smaller than, those 
reported in other studies of environmental 131I 
exposure (Davis et al. 2004; Lyon et al. 2006), 
primarily because all the participants had indi-
vidual thyroid radioactivity measurements 
taken shortly after the accident. Two sources 
of uncertainty in thyroid dose estimates in 
our study, accounting for > 95% of overall 
uncertainty, were thyroid mass of the subject 
at the time of the measurement and measured 
radioactivity in thyroid (Likhtarev et al. 2003). 
Because the error for thyroid mass is likely to 
be a mixture of classical and Berkson error, 
and the error for direct thyroid measurement 
is largely classical, our study should have a 
mixed error structure. Using data from a study 
of thyroid disease in relation to radiation fall-
out from the Nevada test site, Mallick et al. 
(2002) showed that accounting for measure-
ment error, based on a mixture error model, 
resulted in radiation risk estimates that were 
higher than unadjusted estimates, but < 100% 
higher when all error was assumed to be classi-
cal. Based on these results, it seems reasonable 
to assume that the true radiation risk for hypo-
thyroidism is likely to be higher than what we 
report here, although with greater uncertainty.
It is well known that high thyroid doses 
received during therapeutic external irradia-
tion of the head and neck for childhood can-
cer (ranging from 30 to 70 Gy) and from 
131I radiotherapy for Graves disease (typically 
≥ 50 Gy) result in direct killing of thyroid 
cells and lead to subsequent development of 
structural and/or functional abnormalities of 
the thyroid, with primary hypothyroidism 
being the most common thyroid dysfunction 
(Cooper 2005; Hancock et al. 1995; Jereczek-
Fossa et al. 2004). By contrast, data concern-
ing risk of hypothyroidism after diagnostic 131I 
administration and environmental exposure 
due to nuclear weapons tests and releases from 
nuclear reactors have been limited and incon-
sistent (Davis et al. 2004; Larsen et al. 1982; 
Lyon et al. 2006; Takahashi et al. 1999).
Our finding of increased prevalence of sub-
clinical hypothyroidism after 131I exposure is 
in agreement with earlier observations (Larsen 
et al. 1982) but not later ones (Takahashi et al. 
1999) in Marshall Islanders exposed to 131I at 
doses from 1.35 to 3.35 Gy as a consequence 
of nuclear weapons testing. The latter negative 
finding for the Marshallese is consistent with 
the results of the Hanford Thyroid Disease 
Study, which 50 years after exposures from the 
Table 2. Sex- and age-specific ORs and 95% CIs for background prevalence of hypothyroidism (TSH > 4 mIU/L) among individuals exposed to 131I from the 
Chornobyl accident.
  Male  Female
Age at examination (years)  Cases (n)  Noncases (n)  Rate per 1,000  OR (95% CI)a  Cases (n)  Noncases (n)  Rate per 1,000  OR (95% CI)a
12–14  59  566  94.40  1.0 (Referent)  54  567  86.96  1.0 (Referent)
15–19  143  1,623  80.97  0.83 (0.59–1.17)  106  1,639  60.74  0.60 (0.42–0.86)
20–24  83  1,802  44.03  0.46 (0.31–0.67)  95  1,662  54.07  0.53 (0.36–0.76)
25–32  78  1,732  43.09  0.43 (0.29–0.64)  101  1,543  61.43  0.59 (0.40–0.85)
p-Value homogeneity  < 0.001, df = 3  0.01, df = 3
aAnalysis performed with adjustment for place of residency, current smoking status, vitamin consumption, family history of thyroid disease, year and season of examination, ATPO level, 
and 131I thyroid dose based on linear EOR model.Subclinical hypothyroidism after environmental radioiodine exposure
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Hanford nuclear facility (Washington State, 
USA) found no association between hypo-
thyroidism, based on various outcome defini-
tions, and 131I dose estimates [mean (median) 
thyroid dose, 0.20 (0.10) Gy] (Davis et al. 
2004). Reevaluation of thyroid disease risk in 
relation to exposure from the Nevada nuclear 
test site suggested that risk of AIT with hypo-
thyroidism may increase with thyroid dose 
(p = 0.18), but this finding was based on only 
35 cases (Lyon et al. 2006). The data from 
atomic bomb survivors exposed to external 
high-dose-rate gamma irradiation in a range 
from 0 to 4 Gy are also inconsistent (Imaizumi 
et al. 2006; Nagataki et al. 1994). Although in 
an earlier study a significant bell-shaped dose–
response curve for antibody-positive hypothy-
roidism was reported (Nagataki et al. 1994), it 
was not confirmed in a later study (Imaizumi 
et al. 2006). Inconsistent findings in all these 
studies may reflect the unique circumstances of 
population exposure, including different types 
of radiation or mix of radionuclides, dose rates, 
age at exposure, or time since exposure, assum-
ing that radiation risk for hypothyroidism var-
ies by these factors.
Comparison of our study with others   
conducted in populations exposed to the 
Chornobyl fallout during childhood is gener-
ally difficult because previous research lacked 
individual dose estimates. In several studies 
conducted in Belarus and Ukraine, a significant 
upward shift in TSH levels and increased rates 
of juvenile hypothyroidism were reported in 
children living in radionuclide-contaminated 
areas compared with children from uncontami-
nated areas (Goldsmith et al. 1999; Quastel 
et al. 1997; Vykhovanets et al. 1997). The 
remaining ecologic studies were essentially nega-
tive (Kasatkina et al. 1997; Pacini et al. 1998; 
Saiko et al. 1997; Vermiglio et al. 1999).
The observed association between the 
prevalence of subclinical hypothyroidism and 
131I dose in our study, although highly sig-
nificant (p = 0.003), is small, with an estimated 
0.10 EOR/Gy. Nevertheless, this association 
appears to be robust and unlikely to be attrib-
utable to confounding because adjustment for a 
variety of important factors had no meaningful 
effect on the estimate. We found little evidence 
of a departure of the dose response from linear-
ity based on several alternative models. When 
we excluded from the analysis individuals with 
doses ≥ 2 Gy, the EOR per gray, although not 
statistically significant, did not change materi-
ally (EOR/Gy = 0.15), supporting linearity 
of the dose response even at lower dose levels. 
If the true relationship between hypothyroid-
ism prevalence and 131I thyroid dose is close 
to what we observed, most previous studies 
would have had low statistical power to detect 
a relationship.
After controlling for the effect of 131I, 
the relationships with other risk factors for 
hypothyroidism in our study were similar to 
those reported in nonirradiated populations: 
a doubling in risk with elevated ATPO lev-
els (Bjøro et al. 2000; Hollowell et al. 2002; 
Hoogendoorn et al. 2006; Knudsen et al. 1999; 
O’Leary et al. 2006; Pedersen et al. 2003; 
Vanderpump et al. 1995), somewhat increased 
risk with family history of thyroid disease 
(Surks et al. 2004), decreased risk with current 
smoking (Åsvold et al. 2007; Belin et al. 2004; 
Jorde and Sundsfjord 2006), decreased risk 
with intake of vitamins (Zimmermann et al. 
2004), and variation in risk according to geo-
graphical area (Flynn et al. 2004) and season 
of blood draw (Andersen et al. 2003). The age-
related decrease in risk of background preva-
lence of hypothyroidism for both sexes was also 
in agreement with the decline reported in other 
populations of comparable age (Marwaha et al. 
2008; Zurakowski et al. 1999).
The relationship among serum ATPO, 131I, 
and risk of hypothyroidism in our study was 
complex. When included in the same model 
simultaneously, the associations of risk with 131I 
and ATPO were comparable with the respective 
associations when these factors were included 
individually. This observation does not support 
the idea that the radiation-related increase in 
prevalence of subclinical hypothyroidism could 
be attributed to the radiation-related increase 
in prevalence of ATPO that we reported previ-
ously (Tronko et al. 2006a). In fact, we found a 
significant interaction between 131I and ATPO 
level in the prevalence of subclinical hypo-
thyroidism, suggesting that the effects of 131I 
and ATPO were not statistically independent. 
Specifically, individuals with ATPO ≤ 60 U/
mL had a stronger dose–response relationship 
than did individuals with ATPO > 60 U/mL. 
Today, little is known about biological and 
clinical consequences of low doses of 131I on 
the thyroid gland and whether they cause suf-
ficient direct or indirect thyroid damage that 
could result in subclinical hypothyroidism. 
It has been hypothe  sized that the 131I-related 
increase, at least for ATPO antibodies, may be 
Table 3. ORs and 95% CIs with thyroid dose for prevalence of hypothyroidism (TSH > 4 mIU/L) among indi-
viduals exposed to 131I from the Chornobyl accident.
Thyroid dose  Mean dose  Cases  Noncases  Rate
range (Gy)   (Gy)   (n = 719)   (n = 11,134)  per 1,000  ORa (95% CI)
0.00–0.099  0.05  182  3,571  48.49  1.00 (Referent)
0.10–0.249   0.16  167  2,620  59.92  1.11 (0.89–1.39)
0.25–0.49  0.35  121  1,878  60.53  1.08 (0.83–1.39)
0.50–0.99  0.71  105  1,349  72.21  1.31 (1.00–1.72)
1.00–2.49  1.54  86  1,153  69.41  1.27 (0.94–1.71)
2.50–4.99  3.49  36  370  88.67  1.67 (1.09–2.49)
≥ 5.00  9.63  22  193  102.32  1.83 (1.07–3.00)
p-Value for trend = 0.004, df = 1 
aAfter adjustment for effects of sex, age at examination by sex, oblast of residency, current smoking status, vitamin con-
sumption, history of thyroid disease in relatives, year and season of examination, and ATPO level.
Figure 2. Association between prevalence of 
subclinical hypothyroidism and 131I thyroid dose 
estimates: Ukrainian–American cohort study of 
thyroid cancer and other thyroid diseases after the 
Chornobyl accident, 1998–2000. Dose–response 
line was adjusted to pass through the lowest 131I 
dose category. Data points are 131I dose category-
specific ORs with 95% CIs. Line represents fitted 
ORs based on linear EOR model. 
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Table 4. EORs/Gy and 95% CIs for prevalence of 
hypothyroidism (TSH > 4 mIU/L) according to 
selected characteristics among individuals exposed 
to 131I because of the Chornobyl accident.
Characteristic  EOR/Gy (95% CI)a
Sex 
  Male  0.14 (0.03 to 0.33)
  Female  0.07 (–0.01 to 0.19)
  p-Value homogeneityb   0.36, df = 1
Age at exposure, years 
  < 1  0.11 (0.01 to 0.32)
  1–4  0.06 (–0.02 to 0.19)
  5–9  0.12 (–0.03 to 0.36)
  10–14  0.11 (–0.06 to 0.41)
  15–18  0.51 (0.01 to 1.42)
  p-Value homogeneityb   0.56, df = 4
Current smoking status 
  No  0.08 (0.01 to 0.20)
  Yes  0.17 (0.002 to 0.47)
  p-Value homogeneityb   0.46, df = 1
Urinary iodine (µg/L)
  < 20  0.11 (–0.03 to 0.35)
  20–49  0.09 (0.01 to 0.22)
  50–99  0.12 (0.001 to 0.31)
  ≥ 100  0.003 (–0.15 to 0.35)
  Unknown   0.18 (–0.07 to 0.63)
  p-Value homogeneityb   0.92, df = 4
ATPO level (U/mL)
  ≤ 60  0.16 (0.13 to 0.20)
  > 60  –0.14 (–0.22 to 0.15) 
  p-Value homogeneity b   < 0.001, df = 1
aAdjusted for effects of sex, age at examination by sex, 
oblast of residency, current smoking status, vitamin con-
sumption, history of thyroid disease in relatives, year and 
season of examination, and ATPO level. bp-Value based on 
maximum likelihood ratio test.Ostroumova et al.
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transitory (Agate et al. 2008). Given the fact 
that our analysis is cross-sectional in nature 
and that findings from clinical studies concern-
ing the role of antibodies in the development 
of hypothyroidism after 131I therapy are con-
flicting (Ceccarelli et al. 2005; Chiovato et al. 
1998; Mariotti et al. 1986), prospective data are 
needed to characterize the dynamic of radiation-
related risk of hypothyroidism and to confirm 
its relation with ATPO.
In summary, this is the first study to find 
a significant relationship between prevalence 
of hypothyroidism and individual 131I thyroid 
doses due to environmental exposure. The radi-
ation effect was small, a 10% increase per gray, 
and was largely limited to subclinical hypothy-
roidism. Additional data from prospective stud-
ies is required to enhance our understanding of 
the long-term consequences of 131I exposure 
on thyroid function and to clarify what role 
antithyroid antibodies have in this process.
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